spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  cannabinoid 

 HSMN NewsFeed - 30 May 2022
Tetra Bio-Pharma Appoints Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Mar 2022
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi(R) (solriamfetol) to Axsome Therapeutics
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 27 Jan 2022
SciSparc Presents New Leadership Lineup
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jun 2021
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 May 2021
Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2021
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 5 Jan 2021
Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jul 2020
Jay Pharma to File IND Applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination Therapy in Glioblastoma
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Feb 2020
Sara Dakar to Join Jay Pharma as Vice President, Product Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Nov 2019
CTT Pharma Strengthens Board and Management Team
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 2 Aug 2019
InMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announces other Leadership Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jul 2019
Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jul 2019
InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2018
Therapix Biosciences Terminates FSD Acquisition Letter of Intent
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Jun 2018
Intec Pharma Appoints William Bradley Hayes to Board of Directors
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 27 Jun 2018
Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jun 2018
Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2018
Pivot Signs Option Agreement to Acquire Licensing Rights to Patented TriVair(TM) Nasal and Pulmonary Drug Delivery System For Its "RTIC" Ready-To-Infuse-Cannabis Powder
Devices Drug Delivery Licensing
 HSMN NewsFeed - 11 Apr 2018
InMed Announces Appointment of Joshua Blacher as Chief Business Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 4 Apr 2018
Abide Therapeutics Appoints Thomas C. Südhof to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2018
INSYS Therapeutics Appoints Trudy Vanhove to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Mar 2018
Abide and Celgene Enter Worldwide License Agreement for ABX-1772
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Mar 2018
Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Jan 2018
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 28 Dec 2017
GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex(R) (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Dec 2017
FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2017
Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 26 Oct 2017
Intec Pharma Names Walt Linscott as Chief Administrative Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 18 Sep 2017
Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jul 2017
Intec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 3 May 2017
Intec Pharma Announces CEO Change
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 9 Apr 2017
Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 5 Apr 2017
Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 9 Jan 2017
Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2016
Corbus Pharmaceuticals Receives Orphan Designation for Resunab for the Treatment of Cystic Fibrosis in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Sep 2016
Insys Therapeutics Announces CEO Succession Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2016
Kalytera Therapeutics Appoints Dr. Andrew Salzman as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jul 2016
Insys Therapeutics Announces FDA Approval of Syndros(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2016
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2016
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
Biopharmaceuticals Neurology
 HSMN NewsFeed - 19 Jan 2016
Abide Therapeutics Appoints Richard N. Kender to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Nov 2015
Insys Therapeutics Announces Senior Management Changes and Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2015
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 May 2015
GW Pharmaceuticals Initiates Phase 3 Pivotal Study of Epidiolex(R) (CBD) in Lennox-Gastaut Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Jul 2014
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Dravet Syndrome, a Rare Form of Epilepsy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 11 Jun 2014
RuiYi Closes $4 Million Venture Loan from Silicon Valley Bank
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Feb 2014
GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jan 2014
Ipsen and GW Pharmaceuticals plc Enter into Agreement for Ipsen to Promote and Distribute Sativex(R) in Latin America
Biopharmaceuticals Neurology Distribution
 HSMN NewsFeed - 13 Jan 2014
Insys Announces Details of Product Development Pipeline
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 5 Aug 2013
GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Jul 2013
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jul 2013
GW Pharmaceuticals plc Announces Sativex(R) Launch in Italy
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 5 Jan 2012
INSYS Therapeutics Announces FDA Approval of SUBSYS(R) Fentanyl Sublingual Spray
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Dec 2011
INSYS Therapeutics Announces Addition of VP of Marketing to Commercial Team
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 30 Mar 2011
Cara Therapeutics Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Oct 2010
Infinity Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 21 Jul 2010
Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 Mar 2010
INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 12 Nov 2009
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 17 Oct 2008
CeNeRx BioPharma Completes $15 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Jun 2008
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2008
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Cannasat Therapeutics Appoints Dr. Julia Levy to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
Pharmos Corporation Announces Board and Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Dec 2007
Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Oct 2007
Pharmos Restructures Operations in Israel
Biopharmaceuticals
 HSMN NewsFeed - 16 Oct 2007
CeNeRx BioPharma Adds Dr. Daniel Burch as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2007
Rimonabant Regulatory Update in the United States
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2007
FDA Advisory Committee Did Not Recommend Approval of Rimonabant (ZIMULTI(R)) for Use in Obese and Overweight Patients With Associated Risks Factors
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 22 Feb 2007
Valeant Pharmaceuticals Files Investigational New Drug Application for Cesamet(R) in Cancer Chemotherapy-Induced Neuropathic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Feb 2007
Valeant Pharmaceuticals Acquires Rights to Nabilone in United Kingdom and Europe
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2007
Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-induced Pain
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Merck Remains Confident in Future Growth as it Executes on New Strategy
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2006
Rimonabant Update in the United States
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 5 Dec 2006
New Data Shows Rimonabant Benefited Patients with Type 2 Diabetes by Improving Blood Sugar Control, Reducing Weight and Acting on Other Cardiometabolic Risk Factors
Biopharmaceuticals Endocrinology Cardiology
 HSMN NewsFeed - 2 Nov 2006
Par Announces Termination of Cesamet(TM) Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2006
Pharmos Shareholders Approve Vela Pharmaceuticals Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Aug 2006
Valeant Pharmaceuticals Announces U.S. Availability of Cesamet(TM) (CII) and Initiates Post-Marketing Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII)
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 18

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 18 additional stories matching:
cannabinoid
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.